Article

Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemia

2026-04-24

Abstract excerpt

<h4>ABSTRACT</h4> Chimeric Antigen Receptor (CAR) therapy for Acute Myeloid Leukemia (AML) is hindered by disease heterogeneity, antigen overlap with normal hematopoiesis, and the persistence of leukemic stem cells (LSCs). To overcome these barriers, we employed the IF-BETTER strategy to simultaneously target CD33 and the LSC-associated marker TIM-3 by pairing a second-generation CAR with a Cytokine-Costimulatory...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fe454a72-370b-52c1-9cf6-cc9dba586959
DOI: 10.64898/2026.04.22.719217

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemiaDOI 10.64898/2026.04.22.719217Read

The tandem CD33-CLL1 CAR-T as an approach to treat acute myeloid leukemia.Semantic proximity Read

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AMLSemantic proximity Read

CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.Semantic proximity Read

Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.Semantic proximity Read

TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical OutcomesSemantic proximity Read

CD33 Epitope Editing Unlocks UM171-Expanded Cord Blood Grafts for AML ImmunotherapySemantic proximity Read

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Semantic proximity Read

Epitope Engineered Human Haematopoietic Stem Cells are Shielded from CD123-targeted ImmunotherapySemantic proximity Read

Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cellsSemantic proximity Read

CD33 <sup>KO</sup> -CD33-mesothelin loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemiaSemantic proximity Read

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid LeukemiaSemantic proximity Read